SR One is a biotechnology venture capital firm dedicated to partnering with founders and entrepreneurs to transform innovative science into life-saving medicines. With a focus on strong fundamentals, clear development pathways, and novel disease approaches, SR One supports the journey from science to medicine, ensuring groundbreaking advancements in the biotech industry.
We're tracking SR One Capital Management's market expansion
How SR One Capital Management's international expansion compares to its competitors
SR One Capital ManagementYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 SR One Capital ManagementYou | 0 | 0 | — | 0 | 0 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Haisco Pharmaceutical licenses global rights for HSK39004, a dual PDE3/4 inhibitor for COPD, to AirNexis for up to $1.063 billion, marking a breakthrough in Chinese respiratory innovation.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about SR One Capital Management's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
